AD109
Obstructive Sleep Apnea (OSA)
Phase 3Active
Key Facts
About Apnimed
Apnimed is a private, clinical-stage biotech founded in 2013, pioneering oral pharmacologic treatments for obstructive sleep apnea (OSA). The company's lead program, AD109, has reported positive Phase 3 topline data, positioning it as a potential first-in-class oral therapy for a condition affecting tens of millions of people. Apnimed's approach targets the neuromuscular root cause of airway collapse during sleep, aiming to offer a more accessible and acceptable treatment option compared to cumbersome devices. The company is advancing a pipeline of small molecule candidates to address a significant unmet need in a large, underserved market.
View full company profileTherapeutic Areas
Other Obstructive Sleep Apnea (OSA) Drugs
| Drug | Company | Phase |
|---|---|---|
| SCI-110 | SciSparc | Preclinical |
| Inspire 4.0 / Next-Gen System | Inspire Medical Systems | Development |
| DeltaWave CPAP Nasal Pillow System | Remsleep | Commercial |
| Sleep Apnea Biomarker Services | The Siesta Group | Service Offering |
| Injectable Neurostimulation System | Invicta Medical | Proof-of-Concept |
| IHL-42X | Incannex Healthcare | Phase 2/3 |